Metraipolis › archive › dc_cc6beea905ce

Durable clinical benefit from gefitinib plus bevacizumab in a non-small cell lung cancer patient with an acquired C797S mutation following osimertinib… — Europe PMC PMID:41158851

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41158851
DOI: 10.3389/fonc.2025.1673836
License (as archived): solo-consultazione
Archived: 2026-11-09T09:04:06.405Z
SHA-256 of the archived text: 86909bd14c4bd3d88d7c375bbd5ce59d7c8c97e5d560a8f71d24d5a865ee228d
Stable URL of this page: https://metraipolis.com/documento/dc_cc6beea905ce

How to cite

Durable clinical benefit from gefitinib plus bevacizumab in a non-small cell lung cancer patient with an acquired C797S mutation following osimertinib… — Europe PMC PMID:41158851 — Europe PMC (en), https://europepmc.org/article/MED/41158851 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cc6beea905ce (Metraipolis archive dc_cc6beea905ce, sha256 86909bd14c4bd3d88d7c375bbd5ce59d7c8c97e5d560a8f71d24d5a865ee228d)

BibTeX

@misc{dccc6beea905ce,
  title = {Durable clinical benefit from gefitinib plus bevacizumab in a non-small cell lung cancer patient with an acquired C797S mutation following osimertinib… — Europe PMC PMID:41158851},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41158851},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cc6beea905ce; sha256 86909bd14c4bd3d88d7c375bbd5ce59d7c8c97e5d560a8f71d24d5a865ee228d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41158851. Agents can read the archived copy with the MCP tool read_document.